Devoted to our commitment
Our journey continues to evolve, thanks to constant feedback from our diverse team of experts, who are dedicated to addressing the unmet clinical needs associated with mitochondrial dysfunction
Our vision
We strive to be a global leader in the development of novel mitochondrial cell therapies to treat people stricken with diseases of mitochondrial dysfunction. Every day, together with the world's leading scientists, clinicians, and patient advocacy groups, we are translating our mitochondrial science into meaningful therapies for multiple disorders associated with mitochondrial dysfunction.
Minovia’s logo contains Starlings in Flight.
Flying together, constantly pivoting without colliding, symbolizing close collaboration with constant communication in a dynamic atmosphere.
Key Accomplishments to Date
Our ability to execute is driven by our highly experienced executive team, comprehensive regulatory strategy and clinical development plan in partnerships with key physicians and advisors.
Leadership
Natalie Yivgi-Ohana, PhD
Co-founder & CEO
X
Natalie Yivgi-Ohana, PhDCo-founder & CEO
Natalie is a life science entrepreneur; led the company since incorporation in 2012. Natalie has twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with a passion to help children and adults with mitochondrial diseases worldwide.
Noa Sher, PhD
Chief Scientist
X
Noa Sher, PhDChief Scientist
Noa is highly experienced research leader in the cell therapy space and a molecular and cellular biologist by training. Noa received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral studies at the Whitehead Institute, MIT, Cambridge, MA and at the Technion Institute of Technology in Israel. She joined Minovia after several years as head of a research team heading preclinical development and characterization of all clinical-stage products at Pluristem, an Israeli-based cell therapy company.
Shai Melcer, LL.M., Ph.D.
Chief Business Officer
X
Shai Melcer, LL.M., Ph.D.Chief Business Officer
Shai is a multi-disciplinary executive and entrepreneur with 25 years of leadership in business, government, academia and NPO’s. Former CEO of BIOHOUSE, designed and established a biomedical business platform of R&D sites in medical centers, entrepreneurs and strategic partners from industry and investment. Shai holds an LL.B., LL.M. (business) and Ph.D. (Genetics), all from The Hebrew University of Jerusalem and is a certified Attorney and Mediator.
Amnon Eylath, ALM
VP Head of Global Quality
X
Amnon Eylath, ALMVP Head of Global Quality
Amnon is a seasoned quality executive, experienced in the complete life cycle of drug development, covering biotech, pharmaceutical and cell therapy products, from the R&D stage through nonclinical and toxicological safety studies, clinical trials, process and method development, GMP manufacturing, facility validation, support of regulatory submissions for US/EU/MHRA clinical trials and product approvals, to global distribution of commercial drug products. Amnon has established effective and compliant GXP Quality Systems in the US, Switzerland, EU, and the UK, and managed GXP compliance programs for global clinical trials, for US and International Health Authority inspections (FDA, EMA, MHRA), including for-cause inspections. Amnon is recognized as a thought-leader on the Phase-Appropriate application of GMP to drug development, and on the application of Science and Compliance-based Quality oversight. Amnon has been a volunteer at the ISPE and PDA professional organizations, collaborating with FDA and international regulators on various programs and technical reports.
Nadav Eshkol
Director of Process Development and Manufacturing
X
Nadav EshkolDirector of Process Development and Manufacturing
Nadav has more than 10 years of experience in the world of cell therapy, focusing on process development and manufacturing.
He is an expert in developing complex cell therapy processes, optimization, scale-up, tech transfer from development to manufacturing, and process implementation in the manufacturing line, both in start-ups, and in large manufacturing companies.
Before joining Minovia, Nadav led the departments of development and manufacturing at Pluristem, an Israeli-based cell therapy company.
Limor Lior
VP People and Culture
X
Limor LiorVP People and Culture
Limor is an experienced senior HR leader with over 18 years of experience in health-tech companies. She has deep professional knowledge of the biotech field, and personal experience as a manager. Before joining Minovia, Ms. Lior worked at Pluristem Therapeutics in various multi-disciplinary roles, including Manufacturing Manager and Organizational Development Senior Manager, and HRBP. She holds an MSc. in Biotechnology Engineer from the Technion, and she’s a certified coach, mediator and group facilitator. Limor is dedicated to the organization’s people, culture, and their continued development, and has a passion for innovative technologies that impact human life.
Board of Directors
John Cox, MBA
Chairman of the Board
X
John Cox, MBAChairman of the Board
John joined Minovia Therapeutics in February 2019 and brings over 25 years of experience in biopharmaceuticals. Mr. Cox is currently the Chief Executive Officer of Repertoire Immune Medicines, and was formerly the CEO of Bioverativ, which he built and grew from a new venture with two drugs, Eloctate® and Alprolix® for the treatment of hemophilia A and B. In February 2018 Mr. Cox led Bioverativ to a successful acquisition by Sanofi for $11.6B.
Maha Radhakrishnan, MD
Board Member
X
Maha Radhakrishnan, MDBoard Member
Maha joined Minovia Therapeutics bringing significant experience across a broad range of therapeutic areas and disciplines, including CNS (neurology and psychiatry), rheumatology and immunology, rare blood disorders, ophthalmology, cardiology, diabetes, and internal medicine. Maha is currently CMO of Biogen, and formerly held senior medical roles in Sanofi, Bioverativ, BMS, Cephalon, and United Health Group before joining Biogen in 2013.
Natalie Yivgi-Ohana, PhD
Co-founder, CEO & Board Member
X
Natalie Yivgi-Ohana, PhDCo-founder, CEO & Board Member
Natalie is a life science entrepreneur; led the company since incorporation in 2012. Natalie has twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with passion to help children ans adults with mitochondrial diseases worldwide.
Ephraim Aharonson, PhD
Co-founder & Board Member
X
Ephraim Aharonson, PhDCo-founder & Board Member
Efraim is an Ex-Deputy Head, Israel Institute for Biological Research. He is a former executive at Siemens Israel and a serial angel investor in Israeli start-up companies.
Zeev Milbauer
Board Member
X
Zeev MilbauerBoard Member
Zeev is an Angel investor and member of the board of several companies. Zeev is the former Chief Executive Officer and Partner at I.B.I. Investment Banking and brings years of vast experience in brokerage and investment banking.
?